cells

Leadership

Terry Rosen

Terry Rosen, PhD

Chief Executive Officer

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression

arrow
Juan Jaen

Juan Jaen, PhD

President

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years

arrow
Jennifer Jarrett

Jennifer Jarrett

Chief Operating Officer

Ms. Jarrett is an accomplished executive in the healthcare and technology industries.  She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc.,  and prior to this, was Chief Operating Officer and Chief Financial Officer of Arcus Biosciences. Ms. Jarrett has been an ongoing member

arrow
Bob Goeltz

Bob Goeltz

Chief Financial Officer

Mr. Goeltz has an extensive track record and breadth of experience in finance and accounting, most recently serving as Chief Financial Officer and Senior Vice President of UNITY Biotechnology and immediately before that as Chief Financial Officer of

arrow
Kartik Krishnan

Kartik Krishnan, MD, PhD

Chief Medical Officer

Dr. Krishnan has extensive expertise developing oncology medicines, spanning the biopharma industry, academia and clinical settings. He joins Arcus in 2019 and has been responsible for the strategy, design and execution associated with Arcus’s broad clinical development program. Prior to Arcus,

arrow
Eric Matthews

Eric Matthews

Chief Commercial Officer

Mr. Matthews has more than 20 years of experience in biopharmaceuticals in roles spanning global product strategy, marketing, and product development as well as US marketing and sales leadership. Over his career, he has launched 15 new medicines, including Avastin®, Tarceva®, Tecentriq®, and Imfinzi®.

arrow
Jonathan Yingling

Jonathan Yingling, PhD

Chief Scientific Officer

After several years as a member of the Arcus Scientific Advisory Board, in 2020 Jonathan joined Arcus as Senior Vice President, Research. As a member of the Research Leadership team, Jonathan provides guidance to all aspects of our research, discovery and translational efforts, creating a key research interface with our Development organization.

arrow
Carolyn Tang

Carolyn Tang, JD

General Counsel

Ms. Tang is an attorney with broad expertise in transactions, intellectual property, securities, and corporate governance in the US and Europe. Prior to joining Arcus, she worked at Medivation as well as InterMune, where she oversaw InterMune’s global IP portfolio and supported

arrow
Patty Carlos

Patricia Carlos

SVP, Regulatory and Quality

Patty Carlos has more than 20 years of experience in regulatory affairs leading activities across program lifecycles from investigational new drug application (IND) to commercialization. She joined Arcus in 2019

arrow
Jay Powers

Jay Powers, PhD

SVP, Drug Discovery

Dr. Powers has a remarkable track record of success in drug discovery spanning 25 years. Most recently, Jay was VP of Drug Discovery at Flexus Biosciences and then FLX Bio. At Flexus he oversaw drug design efforts in the IDO inhibitor program before it was acquired by BMS. He was previously

arrow
Nigel Walker

Nigel Walker, PhD

SVP, Protein Therapeutics

Dr. Walker has a distinguished career in drug discovery with more than 35 years of experience in the pharmaceutical, biotechnology and chemical industries. Prior to joining Arcus, Dr. Walker was the Executive Director of Amgen’s Molecular Structure & Characterization division leading over 80 staff engaged in providing company-wide analytical & biophysical

arrow
Steve Young

Steve Young, PhD

SVP, Technology & Quantitative Biology

Dr. Young has held scientific, technical, and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences and FLX Bio. He was the first scientist at Flexus and built the company’s biology and IT/informatics functions from the ground up

arrow